Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
{"title":"Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.","authors":"Akira Kabashima, Koichi Kimura, Kensakuet Sanefuji, Soichiro Maekawa","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and\nfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete\nresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection\nand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple\nliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.\nComputed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver\nmetastases could not be identified using CT after the end of the sixth course. Grade 1peripheral\nneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was\nchanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the\nregimen change.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"108 1","pages":"8-13"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukuoka igaku zasshi = Hukuoka acta medica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and
feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete
response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection
and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple
liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.
Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver
metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral
neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was
changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the
regimen change.